Summary
The pharmacokinetics of intravenous chloramphenicol has been studied in 42 patients with liver disease and in 8 controls. The half-life of chloramphenicol (t1/2) was increased in the various liver disorders, the metabolic clearance rate (MCR) and apparent volume of distribution (Vd) were decreased and the area under the time — concentration curve (AUC) showed an increase. The t1/2 of chloramphenicol showed a significant correlation with serum albumin and prothrombin time index.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Glazko AJ, Wolf LM, Dill WA (1949) Biochemical studies on chloramphenicol (chloromycetin). I. Colorimetric methods for the determination of chloramphenicol and related compounds. Arch Biochem 23: 411–418
Ley HL, Jr., Smadel JE, Crocker TT (1948) Administration of chloromycetin to normal human subjects. Proc Soc Exp Biol 68: 9–12
Smith JA, Butler TC, Poole DT (1973) Effect of protein depletion in guinea pigs on glucuronate conjugation of chloramphenicol by liver microsomes. Biochem Pharmacol 22: 981–983
Mehta S, Kalsi HK, Jayaraman S, Mathur VS (1975) Chloramphenicol metabolism in children with protein — calorie malnutrition. Am J Clin Nutr 28: 977–981
Kunin CM, Glazko AJ, Finland M (1959) Persistance of antibiotic with acute renal failure. II. Chloramphenicol and its metabolic products in the blood of patients with severe renal disease or hepatic cirrhosis. J Clin Invest 38: 1498–1508
Azzollini F, Gazzaniga A, Lodola E, Natangelo R (1972) Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver. Int. J Clin Pharmacol 6: 130–134
Shurland LG, Weisberger AL (1963) Chloramphenicol toxicity in liver and renal disease. Arch Intern Med 112: 747–754
Dameshek W (1969) Chloramphenicol aplastic anemia in identical twins. A clue to pathogenesis. N Engl J Med 281: 42–43
Levine PH, Regelson W, Holland JF (1970) Chloramphenicol associate encephalopathy. Clin Pharmacol Ther 11: 194–199
Craft AW, Brocklebank JT, Hay EN, Jackson RH (1974) The ‘grey todder’ chloramphenicol toxicity. Arch Dis Childh 49: 235–237
Levine J, Fischback H (1951) The chemical determination of chloramphenicol in biological materials. Antibio Chemother 38: 59–65
Notari RE, DeYoung JL, Anderson RC (1975) Biopharmaceutics and Pharmacokinetics. An introduction. 2nd edit. Marcel Dekker, New York
Lindberg AA, Nilsson LH, Bucht H, Kallings, LO (1966) Concentration of chloramphenicol in the urine and blood in relation to renal function. Br Med J 2: 724–728
Watanabe A (1974) Effect of chronic administration of centrally acting compounds on chloramphenicol metabolism in schizophrenic patients. Pharmacol 11: 253–256
Levy AJ, Sherlock S, Walker D (1968) Phenylbutazone and isosiazid metabolism in patients with liver disease in relation to previous durg therapy. Lancet 1: 1275–1279
Remmer H (1970) The Role of the liver in drug metabolism. Am J Med 49: 617–629
Datta, DV (1976) Review: Non-cirrhotic portal fibrosis (Idiopathic portal hypertension) in India. J Assoc Phys India 24: 511–527
Datta DV, Nair R, Nair CR (1975): Estimation of hepatic bilirubin UDP-glucuronyl transferase in patients with noncirrhotic portal fibrosis and liver disease. Significance and limitations. Am J Dig Dis 20: 961–971
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Narang, A.P.S., Datta, D.V., Nath, N. et al. Pharmacokinetic study of chloramphenicol in patients with liver disease. Eur J Clin Pharmacol 20, 479–483 (1981). https://doi.org/10.1007/BF00542103
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542103